Advances and controversies in the management of T4 colon cancer

doi:10.3748/wjg.125373

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 48

This Article

(3)

(0)

(340)

Peer-Review Report of This Article

Supplementary Materials of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Evidence Review

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Dec 28, 2026; 32(48): 125373
Published online Dec 28, 2026. doi: 10.3748/wjg.125373

Full Size Figure Download Figure

Figure 2 Risk of recurrence or persistent disease. RR: Risk ratio; CI: Confidence interval; NAC: Neoadjuvant chemotherapy. Citation: Morton D, Seymour M, Magill L, Handley K, Glasbey J, Glimelius B, Palmer A, Seligmann J, Laurberg S, Murakami K, West N, Quirke P, Gray R; FOxTROT Collaborative Group. Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial. J Clin Oncol 2023; 41: 1541-1552. Copyright ©The Author(s) 2023. Published by American Society of Clinical Oncology[23]. The article is open access (Supplementary material).

Citation: Li L, Kong QB, Sui X, Wang XJ. Advances and controversies in the management of T4 colon cancer. World J Gastroenterol 2026; 32(48): 125373
URL: https://www.wjgnet.com/1007-9327/full/v32/i48/125373.htm
DOI: https://dx.doi.org/10.3748/wjg.125373

Li L, Kong QB, Sui X, Wang XJ. Advances and controversies in the management of T4 colon cancer. World J Gastroenterol 2026; 32(48): 125373 [DOI: 10.3748/wjg.125373]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.